|
MOLMED is a medical biotechnology company located in Milan, inside the San Raffaele Biomedical Science Park〔(【引用サイトリンク】title= Biomedical Science Park Raf – Sviluppo Economico della Provincia di Milano )〕(which houses the San Raffaele research hospital and Scientific Institute, and a private university). The company was founded by Claudio Bordignonin 1996 as a joint venture between Science Park Raf and Boehringer Mannheim,〔(【引用サイトリンク】title= MolMed History )〕 in order to create a cGMP structure specialised in the ''ex vivo'' manipulation of human cells for supplying gene and cell therapy services for clinical trial protocols.〔(【引用サイトリンク】title= MolMed - San Raffaele Biomedical Science Park )〕 MolMed activities cover all functions, from discovery to proof of clinical activity, focuses on oncology indications that require new therapy options and has an in-house GMP-based manufacturing of cell and gene therapy products. MolMed's product portfolio contains two therapeutic antitumour drugs undergoing clinical trial: TK cell therapy product that permits bone marrow transplant from donors that are partially compatible with the patient, in Phase III for the treatment of high-risk leukaemia;〔(【引用サイトリンク】title= MolMed Clinical Development Update: Six Abstracts Accepted for Presentation at ASCO 2012 )〕 NGR-hTNF (antitumor recombinant protein),〔(【引用サイトリンク】title= MolMed NGR-hTNF four studies accepted for presentation at ASCO 2013 )〕 a recombinant biological drug that targets tumour blood vessels, in Phase III in malignant pleural mesothelioma and in Phase II in six other indications: colorectal, liver and ovarian cancers, small-cell lung cancer, non-small cell lung cancer and in soft-tissue sarcomas. MolMed also provides high-level competencies in gene and cell therapy for the development, performance and validation of projects for third parties; said competencies range from preclinical studies to Phase III clinical trials, including the production in compliance with current GMP of viral vectors and patient-specific genetically modified cells for clinical use. ==History== MolMed was founded in 1996〔(【引用サイトリンク】title= MolMed Likely to Seek Partner for Cancer Drug )〕〔(【引用サイトリンク】title= MLM:BrsaItaliana )〕 as a joint venture between Science Park Raf and Boehringer Mannheim, with the objective of creating a cutting-edge cGMP structure, specialized in the ex vivo manipulation of human cells for the supply of gene therapy services for clinical trial protocols. In the course of the first three years, Boehringer Mannheim was acquired by Roche which then sold its equity stake in MolMed to the EDCP venture capital fund. In 2000, MolMed's corporate model changed the service company into a biopharmaceutical product company, and the company developed further, adding the operations typical of a biopharmaceutical development company to its service business, with a focus on new therapies for the cure of cancer.〔(【引用サイトリンク】title= Company Overview )〕 In fact in 2002, there was the acquisition and incorporation of Genera S.p.A., the San Raffaele Scientific Institute's research company. In 2004, there was the entrance of three important private Italian investors in MolMed:Fininvest, Herule Finance (today H-Equity S.r.l.) and La Leonardo Finanziaria〔(【引用サイトリンク】title= 4.2 billion euros appear in the cash )〕 (today Delfin S. à r.l.). The company was listed on the Milan Stock Exchange in 2008〔(【引用サイトリンク】title= MolMed Board of Directors Reviews 2007 Financial Statements )〕 with an IPO of 25% of its shares, resulting in 56 million Euro gross proceeds. The total number of shares issued was 105,207,808 (100% ordinary shares with no par value). Today total number of issued shares is 231,058,594〔(【引用サイトリンク】title= Shareholders' information )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「MolMed」の詳細全文を読む スポンサード リンク
|